World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
42035
World Ranking
10711
National Ranking
5508

Overview

Lynn M. Schuchter is affiliated with the University of Pennsylvania in the United States. Their work primarily spans the fields of Medicine and Immunology and Microbiology, with a strong focus on Oncology within these domains. Schuchter's research includes significant contributions to cancer immunotherapy, immune response mechanisms, and melanoma management.

The main topics covered in Schuchter's research include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Palliative Care and End-of-Life Issues
  • Cutaneous Melanoma Detection and Management
  • Immune Cell Function and Interaction
  • Melanoma and MAPK Pathways

In terms of subfields, their publications largely focus on:

  • Oncology
  • Immunology
  • Molecular Biology
  • Public Health, Environmental and Occupational Health
  • General Health Professions

Schuchter has published extensively, with frequent appearances in notable journals such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cell Reports
  • JAMA Oncology
  • Clinical Cancer Research

Their recent published papers include:

  • "Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms" (2020, Immunity)
  • "Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer" (2020, Cell Reports)
  • "Effect of Integrating Machine Learning Mortality Estimates With Behavioral Nudges to Clinicians on Serious Illness Conversations Among Patients With Cancer" (2020, JAMA Oncology)
  • "Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy" (2020, JNCI Journal of the National Cancer Institute)
  • "ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression" (2022, Developmental Cell)

They have collaborated frequently with several researchers in the field, including:

  • Ravi K. Amaravadi
  • Tara C. Mitchell
  • Giorgos C. Karakousis
  • Xiaowei Xu
  • Alexander C. Huang

Best Publications

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response

    Gang Chen;Alexander C. Huang;Wei Zhang;Wei Zhang;Gao Zhang

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

    Christina Twyman-Saint Victor;Andrew J. Rech;Amit Maity;Ramesh Rengan;Ramesh Rengan

  • T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

    Alexander C. Huang;Michael A. Postow;Michael A. Postow;Robert J. Orlowski;Rosemarie Mick

  • TOX transcriptionally and epigenetically programs CD8 + T cell exhaustion

    Omar Khan;Josephine R. Giles;Sierra McDonald;Sasikanth Manne

  • Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.

    Joseph L. Benci;Bihui Xu;Yu Qiu;Tony J. Wu

  • Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

    Jean-Christophe Beltra;Sasikanth Manne;Mohamed S. Abdel-Hakeem;Makoto Kurachi

  • Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

    Paul B. Chapman;Lawrence H. Einhorn;Michael L. Meyers;Scott Saxman

  • Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.

    Sandra L. Wong;Charles M. Balch;Patricia Hurley;Sanjiv S. Agarwala

  • Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

    T Eisen;T Ahmad;K T Flaherty;M Gore

  • American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

    Martee L. Hensley;Karen L. Hagerty;Tarun Kewalramani;Daniel M. Green

  • Enhancing CD8 + T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.

    Ying Zhang;Ying Zhang;Raj Kurupati;Ling Liu;Xiang Yang Zhou

  • A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

    Alexander C. Huang;Robert J. Orlowski;Robert J. Orlowski;Xiaowei Xu;Rosemarie Mick

  • American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.

    Martee L. Hensley;Lynn M. Schuchter;Celeste Lindley;Neal J. Meropol

  • Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma

    Xiao Hong Ma;Sheng Fu Piao;Souvik Dey;Quentin McAfee

  • Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

    Kerstin Trunzer;Anna C. Pavlick;Lynn Schuchter;Rene Gonzalez

  • Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma

    Reshma Rangwala;Yunyoung C. Chang;Janice Hu;Kenneth M. Algazy

  • Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.

    Julia Tchou;Yangbing Zhao;Bruce L Levine;Paul J Zhang

  • Phase I II M ulticenter R andomized T rial o f t he D artmouth Regimen V ersus D acarbazine i n P atients With M etastatic M elanoma

    Paul B. Chapman;Lawrence H. Einhorn;Michael L. Meyers;Scott Saxman

Frequent Co-Authors

Ravi K. Amaravadi
Ravi K. Amaravadi University of Pennsylvania
Xiaowei Xu
Xiaowei Xu University of Pennsylvania
Keith T. Flaherty
Keith T. Flaherty Harvard University
David E. Elder
David E. Elder Hospital of the University of Pennsylvania
Katherine L. Nathanson
Katherine L. Nathanson University of Pennsylvania
Wei Xu
Wei Xu Shenzhen University
Robert H. Vonderheide
Robert H. Vonderheide University of Pennsylvania
Rosemarie Mick
Rosemarie Mick University of Pennsylvania
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Meenhard Herlyn
Meenhard Herlyn The Wistar Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always follow a single path. Outside the traditional MD programs, a range of online healthcare degrees can prepare you for rewarding roles across the healthcare sector.

For example, aspiring nurses might wonder, do you have to take the teas test to get into nursing school? Some top institutions offer flexible entry routes for those looking to start a nursing career without standardized tests.

If you are interested in leadership and behind-the-scenes roles in healthcare, consider a healthcare administration degree online. This program emphasizes business, management, and policy-making within medical settings.

Licensed registered nurses wishing to advance their careers can pursue rn to fnp bridge programs, which provide a streamlined transition toward becoming a Family Nurse Practitioner through online study.

Alternatively, nutrition science offers growing opportunities for online learners. Earning an online degree nutrition can lead to careers in patient education, wellness coaching, or clinical nutrition.

These pathways offer flexibility, accessibility, and diverse career options—all while addressing the evolving demands of healthcare in the USA.

Best Scientists Citing Lynn M. Schuchter

Trending Scientists